The development of hormonal treatments for so‐called “hormone‐dependent” breast cancers (ER‐positive, estrogen receptor‐positive) was driven by the understanding of the role of ER in breast cancer and the identification of mechanisms for its blockade. Here, ESR1 is linked to breast carcinoma.